4 received vehicle buffer alone and three experimental groups (n=6 each) that received rhBMP-7 at 30 mg/kg, 100 mg/kg and 300 mg/kg. Due to the different kinetics of disease progression,
COL4A3
-/-mice were treated for 8 weeks and the study was terminated at the age of 14 weeks.
Col4A3
-/-mice (n=14) were divided into a control group (n=7) that received vehicle buffer alone and a treatment group that received 300 mg/kg rhBMP-7. rhBMP-7 was administered intraperitoneally (i.p.) three times a week. Serum was obtained every two weeks from baseline to death on all mice. Urine was collected every two weeks in metabolic cages.
Histologic Assessment of renal injury.
Tissue from kidneys, liver, heart, spleen and brain was fixed in 4% paraformaldehyde and embedded in paraffin. Sections were stained with hematoxylin and eosin (HE), Masson's Trichrome Stain (MTC), as well as with periodic acidSchiffs stain (PAS). Extent of renal injury was estimated by morphometric assessment of the tubulointerstitial injury and glomerular damage. The relative interstitial volume was evaluated by morphometric analysis using a 10 mm 2 graticule fitted into the microscope. Five randomly selected cortical areas, which included glomeruli, were evaluated for each animal (5, 45) .
Tubules were evaluated for their widened lumen and thickened basement membranes to estimate percentage of atrophic tubules (21) . 100 glomeruli in each kidney were evaluated for crescent formation, the crescentic index reflects the percentage of crescentic glomeruli (47) .
Glomerulosclerosis was scored for severity (0-4, 0=normal, 4=maximum severity) as described by Raij (38) . Nuclei in 50 glomeruli of similar size in each kidney were counted to estimate glomerular cellularity (29) .
Immunohistochemistry. Kidney tissue samples were frozen in liquid nitrogen and processed by indirect immunofluorescence technique as previously described (45) . Frozen Cell Culture: Human interstitial fibroblasts (TK173) were maintained in culture as previously described (27, 32) . For stimulation of fibroblasts, media were replaced with serumfree Iscove's modified Dulbecco's medium (IMDM) (45) .
Direct-enzyme-linked immunoabsorbent assay:
We performed ELISAs for estimation of type I collagen and fibronectin as described previously (43) . Quiescent fibroblasts (8x10 3 cells/ well) were stimulated with rhBMP-7 (1.0, 10.0 and 100 ng/ml) in IMDM medium that was supplemented with 50 mg/ml ascorbic acid and aminopropionitrile (Sigma, St. Louis) for 48 h.
Supernatants were analyzed in Maxisorp‰ (Nunc) plates using primary antibodies raised against type I collagen (Southern Biotechnologies, Birmingham, AL), and fibronectin (Sigma, St.
Louis). All assays were performed in triplicate and repeated at least 3 times. The working range was 10 to 1000ng/ml collagen type I and 0.1 to 10 mg/ml for fibronectin.
Zymography: Zymography was performed as described previously (57) . Briefly, cells (1x10 5 per well) were plated in 6-well plates and grown for 6 h in DMEM medium containing served to restore renal function and morphology (21, 52, 54, 56) . In the present study we attempted to explore the potential of rhBMP-7 to prevent progression of renal disease in genetic models of renal disease. We first assessed endogenous BMP-7 in the normal and diseased Additionally, we used mice that lack the collagen type IV a3 gene (Col4A3
) as a second model for progressive renal disease. Col4A3 -/-mice develop progressive renal disease, which leads to death between week 12 and 16 (1, 30) . While C57BL/6 control mice displayed tubular and glomerular BMP-7 localization, progression of renal disease in Col4A3 -/-mice was associated with a decrease in endogenous BMP-7 expression (Figure 1 C,D) . We thus speculated that supplementation of exogenous rhBMP-7 could improve renal pathology and function in both these genetic mouse models for chronic renal disease.
rhBMP-7 ameliorates progression of chronic renal disease in MRL/MpJ lpr/lpr mice.
To evaluate a potential role for rhBMP-7 in the treatment of chronic renal disease, we first utilized MRL/MpJ lpr/lpr lupus nephritis mice (11) . We initiated i.p. injection of rh BMP-7 at 4 weeks of age. At this age, very early signs of disease could be demonstrated in these mice. After termination of the study at 16 weeks of age, rhBMP-7 treated mice displayed reduced relative interstitial volume as well as a reduced number of atrophic tubular structures when compared to untreated control (Figure 2 A-D) . Animals that were treated with 300 mg/kg rhBMP-7 also displayed reduced glomerular crescents, markedly reduced glomerulosclerosis, and reduced glomerular hypercellularity (Figure 2 E, F) . Serum creatinine levels were significantly reduced in mice that were treated with 300 mg/kg rhBMP-7 after four weeks of treatment, whereas by the end of study results failed to reach significance due to wide variance in the treatment groups ( Figure 2G ).
These findings also correlated with reduced interstitial staining for type I collagen in the treated mice, compared to control mice (Figure 3 A, B) . Localization for IgG in glomeruli did not show substantial difference between untreated and treated mice (Figure 3 C, D) .
Treatment with rhBMP-7 inhibits progression of renal disease in Col4A3 -/-mice.
We next attempted to investigate, whether administration of exogenous rhBMP-7 had a similar role on the progression of renal disease in Col4A3 -/-mice. Treatment with rhBMP-7 was initiated after six weeks of age until the study was terminated at the age of 14 weeks (30) . In this study, we treated mice with 300 mg/kg rhBMP-7, which was established by our previous study as the optimum dosage, and was also confirmed by other groups (21, 52) . Treatment with 300 mg/kg Furthermore, MMP-9 in the interstitium rarely co-localized with a-SMA, suggesting that rhBMP-7 in interstitial fibroblasts activates mainly MMP-2 in the injured kidneys (Figure 5 F, G) .
Discussion
Progression of chronic renal disease towards ESRF still represents one of the biggest problems in nephrology, as it leads to an increasing number of patients who require long-term renal replacement therapy, such as dialysis or kidney transplant (9, 35) . While ACE-inhibitors are currently the most promising therapeutic agents to inhibit progression of renal fibrosis in clinical use, specific therapeutic options are still not available (2, 7, 15, 25, 55) .
In this regard, several recent studies have demonstrated a beneficial role for administration of exogenous rhBMP-7 in different animal models of chronic renal injury (21, 31, 52, 56). BMP-7 is a member of the TGF-b superfamily and has an important function during kidney development (20) . It is associated with condensation of the metanephric mesenchyme, leading to the formation of tubules and glomeruli (20, 41) . In the adult kidney, BMP-7 expression can be detected in tubular epithelial cells and in podocytes (17, 54) . Endogenous BMP-7 expression significantly decreases during acute renal injury and administration of exogenous rhBMP-7 accelerates the repair of the injured kidney, suggesting that BMP-7 plays a role in the maintenance kidney homeostasis (42, 49) . Similarly, BMP-7 expression is decreased in several induced animal models of chronic renal injury, and administration of exogenous rhBMP-7 in these models inhibits progression or enables recovery of chronic renal injury (21, 52, 54, 56) .
In this regard, in the present study we establish for the first time a role of rhBMP-7 as a therapeutic in two genetic mouse models, which mimic long-term chronic renal disease. In MRL/MpJ lpr/lpr mice, which develop lupus nephritis-like renal disease associated with significant tubulointerstitial fibrosis after three months, treatment with rhBMP-7 inhibits progression of renal disease in a dose dependent manner. In mice deficient in the a3 chain of type IV collagen, ESRF associated with interstitial fibrosis after 14 weeks is observed. rhBMP-7 prevents renal fibrosis and renal related mortality in these mice and increases their survival by 12 weeks. Thus, we demonstrate the anti-fibrotic effect of rhBMP-7 in two long-term mouse models for chronic renal fibrosis, providing further evidence for the use of rhBMP-7 as a therapeutic agent for chronic renal injury.
Previous studies have suggested that rhBMP-7 exerts its anti-fibrotic effect mainly on tubular epithelial cells, where it inhibits the release of pro-inflammatory chemokines (17) . It is also shown to reverse epithelial to mesenchymal transition (EMT), while acting as an antagonist of transforming growth factor b1 (TGF-b1)-induced E-cadherin downregulation (56) . In chronic renal fibrosis, activated interstitial fibroblasts, which can either derive from resident interstitial fibroblasts, from tubular epithelial cells via EMT or from bone marrow-derived mesenchymal precursor cells, are considered the main pathogenic mediators of renal disease (13, 19, 22, 39) .
Renal fibrosis is characterized by an excessive deposition of interstitial ECM, which results in destruction of kidney architecture and impairment of renal function. Activated interstitial fibroblasts are the main mediators of enhanced ECM synthesis (3, 6, 14, 16, 33) . In the present study we provide evidence that rhBMP-7 functions (in addition to its effects on tubular epithelial cells) by inhibiting pro-fibrotic contributions of activated interstitial fibroblasts. We hypothesize that up-regulation of MMP-2 by rhBMP-7 reflects increased ECM degradation and thus potentially a decrease in scar tissue in the renal interstitium (46, 58) . TGF-b1, the main pro-fibrotic growth factor involved in renal fibrogenesis, mediates all these three pro-fibrotic features, which are inhibited by rhBMP-7 in our studies, in renal fibroblasts (6, 46) . Previous studies have also demonstrated the potential of rhBMP-7 to counteract TGF-b1 action in tubular epithelial and mesangial cells (53, 56) . Our research coupled with these previous important studies suggest that rhBMP-7 functions on tubular epithelial cells, mesangial cells and fibroblasts to restore the health of kidney tissue. These studies provide us further with confidence that rhBMP-7 should be tested in human clinical trials involving kidney disease patients. Original magnification x200. 
